Paget’s Disease of Bone

  • Roy D. Altman


Paget’s disease is a chronic disorder of the adult skeleton characterized by increased resorption and deposition of bone resulting in replacement of the normal matrix with a softened and enlarged bone. Initially, there is active resorption by large and increased numbers of osteoclasts containing multiple nuclei, followed by deposition of bone by numerous osteoblasts which most often results in a weakened disorganized bony structure that is interspersed with areas of fibrosis. Although localized to isolated areas of the skeleton, there may be widespread bony distribution.


Bone Pain Serum Alkaline Phosphatase Salmon Calcitonin Flulike Syndrome Adult Skeleton 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget’s disease of bone in the United States. J Bone Miner Res 2000;15:461–465.CrossRefPubMedGoogle Scholar
  2. 2.
    Michou L, Collet C, Laplanche JL, Orcel P, Cornelis F. Genetics of Paget’s disease of bone. Joint Bone Spine 2006;73:243–248.CrossRefPubMedGoogle Scholar
  3. 3.
    Kurihara N, Zhou H, Reddy SV, et al. Expression of measles virus nucleocapsid protein in Osteoclasts induces Paget’s disease-like bone lesions in mice. J Bone Miner Res 2006;21:446–455.CrossRefPubMedGoogle Scholar
  4. 4.
    Altman RD. Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 1980;23:1121–1127.CrossRefPubMedGoogle Scholar
  5. 5.
    Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006;144:753–761.PubMedGoogle Scholar
  6. 6.
    Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone 2004;34:747–754.CrossRefPubMedGoogle Scholar
  7. 7.
    Altman RD, Johnston CC, Khairi MRA, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone (osteitis deformans). N Engl J Med 1973;289:1379–1384.CrossRefPubMedGoogle Scholar
  8. 8.
    Vasireddy S. Talwalkar A, Miller H, Mehan R, Swinson DR. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate. Clin Rheumatol 2003;22:376–380.CrossRefPubMedGoogle Scholar
  9. 9.
    Crandall C. Risedronate: a clinical review. Arch Intern Med 2001;161:353–360.CrossRefPubMedGoogle Scholar
  10. 10.
    Morales-Piga A. Tiludronate. A new treatment for an old ailment: Paget’s disease of bone. Expert Opin Pharmacother 1999;1:157–170.CrossRefPubMedGoogle Scholar
  11. 11.
    Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005;353:898–908.CrossRefPubMedGoogle Scholar
  12. 12.
    Martin TJ. Treatment of Paget’s disease with calcitonins. Aust N Z J Med 1979;9:36–43.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Roy D. Altman
    • 1
  1. 1.Deparment of Medicine/Rheumatology and ImmunologyUniversity of California, Los AngelesLos AngelesUSA

Personalised recommendations